株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

抗生物質:技術と世界市場

Antibiotics: Technologies and Global Markets

発行 BCC Research 商品コード 103308
出版日 ページ情報 英文 157 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: BCC Research社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
抗生物質:技術と世界市場 Antibiotics: Technologies and Global Markets
出版日: 2016年03月21日 ページ情報: 英文 157 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界における全身投与の抗生物質市場額は2015年の406億米ドルから、今後は2.0%のCAGRで成長すると見られ、2020年までに447億米ドルに達すると予測されています

当レポートでは、世界の全身投与の抗生物質市場について調査し、市場の概要、世界市場の動向の分析(実績データ・CAGR予測)、市場影響因子の詳細分析、重要な動向・製品に関する議論、および主要企業の包括的なプロファイルなどをご提供しております。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • イントロダクション
  • バクテリア
  • グラム陽性菌
  • グラム陰性菌
  • 細菌感染症
  • 呼吸器感染症
  • 肺炎
  • 結核
  • 抗生物質の定義
  • 抗生物質の歴史と現況
  • 抗生物質耐性菌
  • 抗生物質維持時代の到来
  • 促進因子・阻害因子・機会
  • 主要企業の市場シェア
  • 抗生物質のバリューチェーン
  • 規制の問題
  • 市場に影響を及ぼす主な動向

第4章 抗生物質の研究開発

  • 抗生物質の研究に革新が欠けている理由
  • 抗生物質調査を推進する戦略
  • 希少薬剤の位置づけ

第5章 抗生物質市場:種類別

  • 市場規模推計
  • 市場シェア推計
  • 世界の抗生物質市場:クラス別
  • ベータラクタム系抗生物質
  • キノロン・フルオロキノロン
  • テトラサイクリン
  • マクロライド
  • その他の抗生物質

第6章 動物用抗生物質市場

  • イントロダクション
  • 動物用アプリケーション
  • その他のアプリケーション

第7章 企業プロファイル

第8章 抗生物質に関する治験

  • フェーズII治験における抗生物質
  • フェーズI治験における抗生物質

第9章 バクテリア種類の概要

  • 病原体、診断、臨床所見および治療

第10章 頭字語リスト

図表リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHM025D

REPORT HIGHLIGHTS

The global systemic antibiotics market should reach nearly $44.7 billion in 2020 from nearly $40.6 billion in 2015 at a compound annual growth rate (CAGR) of 2.0% from 2015 to 2020.

This report provides:

  • An overview of the global markets and related technologies for antibiotics.
  • Analyses of global market trends, with data from 2014, 2015, and projections of compound annual growth rates (CAGRs) through 2020.
  • Breakdowns of the market by human application and veterinary application
  • A look at major market trends and the factors driving or inhibiting the growth of the global pharmaceutical antibiotics market and its various submarkets
  • Profiles of key players in the market and analysis of their core competencies and market shares
  • Detailed coverage of
    • Beta-lactams.
      • Penicillin.
      • Cephalosporins.
      • Carbapenems.
    • Fluoroquinolones.
      • Second generation.
      • Third generation.
      • Others.
    • Macrolides.
    • Tetracycline.
    • Other antibiotic classes.

SCOPE OF REPORT

This research report categorizes the systemic antibiotics market into the following segments:

Antibiotics market (human application) by product:

  • Beta-lactams.
    • Penicillin.
    • Cephalosporins.
    • Carbapenems.
  • Fluoroquinolones.
    • Second generation.
    • Third generation.
    • Others.
  • Macrolides.
  • Tetracycline.
  • Other antibiotic classes.
  • Antibiotics market by application:
  • Human applications.
  • Veterinary applications.

Launch of any new antibiotics during the forecast period has not been accounted in the market.

ANALYST'S CREDENTIALS

Neha Maliwal, a graduate in biotechnology and a postgraduate in marketing and biotechnology from the University of Pune (India), is the author of this study and numerous others, including the analyses of related markets such as radiopharmaceuticals, healthcare analytics, radiotherapy devices, healthcare business process outsourcing (BPO), and biotechnology instrumentation.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • RESEARCH METHODOLOGY
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - EXECUTIVE SUMMARY

  • SUMMARY TABLE: GLOBAL ANTIBIOTICS MARKET BY CLASS, THROUGH 2020 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL ANTIBIOTICS MARKET BY CLASS, 2015 AND 2020 ($ MILLIONS)

CHAPTER 3 - MARKET OVERVIEW

  • INTRODUCTION
  • BACTERIA
    • TABLE 1: DIFFERENCES BETWEEN GRAM-NEGATIVE AND GRAM-POSITIVE BACTERIA
  • GRAM-POSITIVE BACTERIA
  • GRAM-NEGATIVE BACTERIA
    • Mycobacterium
      • TABLE 2: CLASSIFICATION OF BACTERIA BY SHAPE
  • BACTERIAL INFECTIONS
  • RESPIRATORY TRACT INFECTIONS
    • Upper Respiratory Tract Infection
      • TABLE 3: PRINCIPLES FOR JUDICIAL USE OF ANTIBIOTICS
      • TABLE 4: INCIDENCE OF UPPER RESPIRATORY TRACT INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)
    • Lower Respiratory Tract Infection
  • PNEUMONIA
    • TABLE 5 COMMON CAUSATIVE MICROBES OF COMMUNITY AND HOSPITAL-ACQUIRED PNEUMONIA
    • Community-acquired Pneumonia
    • Hospital-acquired Pneumonia
      • TABLE 6: PREFERRED PHARMACOTHERAPY FOR MICROORGANISMS CAUSING BACTERIAL PNEUMONIA
      • TABLE 7: INCIDENCE OF COMMUNITY-ACQUIRED PNEUMONIA BY COUNTRY, 2010 (NUMBER/%)
  • TUBERCULOSIS
    • URINARY TRACT INFECTIONS (UTI)
      • TABLE 8: INCIDENCE OF URINARY TRACT INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)
    • SKIN AND SKIN STRUCTURE INFECTIONS
      • TABLE 9: INCIDENCE OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)
      • Cellulitis and Erysipelas
      • Folliculitis
      • Impetigo and Ecthyma
      • Abscesses
      • Carbuncles and Furuncles
    • GYNECOLOGICAL INFECTIONS
      • TABLE 10: INCIDENCE OF BACTERIAL VAGINOSIS INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)
  • DEFINITION OF ANTIBIOTIC
    • CLASSIFICATION OF ANTIBIOTICS
      • FIGURE 1: CLASSIFICATION OF ANTIBIOTICS
  • HISTORY OF ANTIBIOTICS AND CURRENT STATUS
    • PRE-ANTIBIOTIC ERA
    • ANTIBIOTIC ERA
      • TABLE 11: U.S. LIFE EXPECTANCY AT BIRTH, 1920-2013 (YEARS)
      • TABLE 12: ANTIBIOTICS: YEAR OF INTRODUCTION, MODE OF ACTION AND TARGET SPECIES
  • ANTIBIOTIC-RESISTANT BACTERIA
    • MECHANISM OF RESISTANCE
      • TABLE 13: ANTIBIOTICS: MODE OF ACTION
      • Mechanisms of Antimicrobial Resistance
        • TABLE 14: ESTIMATED DEATHS PER YEAR CAUSED BY AMR BY REGION, 2050 (NUMBER)
      • Methods for the Dissemination of Antimicrobial Resistance Genes
      • Resistance to B-Lactam Antibiotics
      • Tetracycline Resistance
      • Chloramphenicol Resistance
      • Aminoglycoside Resistance
      • Quinolone Resistance
      • Macrolide, Lincosamide, and Streptogramin (MLS) Resistance
      • Glycopeptide Resistance
      • Sulfonamides and Trimethoprim Resistance
      • Multidrug Resistance
        • TABLE 15: TYPES OF ANTIBIOTICS AND METHODS OF RESISTANCE
        • TABLE 16: CURRENT AND EMERGING ANTIBIOTIC-RESISTANT BACTERIA
  • EMERGENCE OF POST-ANTIBIOTIC ERA
    • TABLE 17: BIOCHEMICAL MECHANISM OF ANTIBIOTIC RESISTANCE
    • FIGURE 2: CDC LIST OF HIGHLY CONCERNING BACTERIA, ACCORDING TO THREAT LEVEL
    • TABLE 18: ADDITIONAL COST AND LENGTH OF STAY DUE TO ANTIBIOTIC-RESISTANT BACTERIA BY REGION
    • Limitation of Antibiotics
    • Some Antibiotics are Active against Only Certain Kinds of Bacteria
    • Some Bacteria are Virulent and Can Kill Quickly
    • Some Bacteria Grow in Biofilms that cannot be Easily Penetrated by Antibiotics
  • DRIVERS RESTRAINTS AND OPPORTUNITIES
    • DRIVERS
      • Growth of the Global Pharmaceutical Market Driven by Antibiotics
      • Aging Population Propels the Growth of the Antibiotics Market
        • FIGURE 3: INCREASE IN AGING POPULATION, 2011 AND 2050
      • Public-Private Partnerships Encourage Antibiotic Development
      • Increasing Prevalence of Hospital-Acquired Infections Triggers Market Growth
    • RESTRAINTS
      • Antibiotic Resistance
      • Declining R&D Investment Poses Long-Term Barrier to Market Growth
      • Genericization of Antibiotics Restrains Market Growth
    • OPPORTUNITIES
      • Market Expansion into Emerging Countries
      • Multidrug-Resistant Pathogens Provide an Opportunity to Develop Novel Antibacterial Agents
    • BURNING ISSUE
      • New Antibiotic Discovered From Soil
  • MARKET SHARES OF KEY COMPANIES
    • FIGURE 4: GLOBAL MARKET SHARES FOR ANTIBIOTIC COMPANIES, 2014 (%)
  • VALUE CHAIN OF ANTIBIOTICS
    • CHINA IS A BECOMING A CENTER FOR MICROBIAL THREATS
  • REGULATORY ISSUES
    • FDA AND INTERNATIONAL REGULATORY AGENCIES
    • RECENT REGULATORY REFORMS
    • KETEK CASE STUDY
  • KEY TRENDS AFFECTING THE MARKET
    • NEVER EVENTS
      • Impact on the Use of Antibiotics
    • FUNDING FOR NEW ANTIBIOTICS
      • United States
        • Infectious Diseases Society of America
        • NIH Funding
        • Public-Private Partnerships
      • Europe
        • Innovative Medicines Initiative
    • EMERGING DRUGS WITH NOVEL MECHANISMS OF ACTION
      • PharmaSea Project
      • Combination of Different Antibiotics
      • Others

CHAPTER 4 - ANTIBIOTIC RESEARCH AND DEVELOPMENT

  • REASONS FOR LACK OF INNOVATION IN ANTIBIOTIC RESEARCH
    • FIGURE 5: REASONS FOR LACK OF INNOVATION IN ANTIBIOTIC RESEARCH
    • LOW RETURN ON INVESTMENT
    • STRICT REGULATORY ENVIRONMENT
    • SCIENTIFIC CHALLENGES
    • STRATEGIES TO PROMOTE ANTIBIOTIC RESEARCH
      • FIGURE 6: STRATEGIES TO PROMOTE ANTIBIOTIC RESEARCH
    • PUSH STRATEGIES
      • Increasing Access to Research
      • Increasing the Number of Scientific Personnel
      • Direct Funding of Research
      • Translational Research
      • Tax Incentives
      • Product Development Partnerships
    • PULL STRATEGIES
      • Monetary Awards
      • Advance Market Commitments
      • Legal and Regulatory Initiatives
      • Clinical Trials
      • Accelerated Regulatory Review
      • Intellectual Property Rights Strategies
        • Increasing the Term of IP Protection and Data Exclusivity
        • Wildcard Patent Extension
        • Patent Buyouts
      • Pricing and Reimbursement
      • Other Legal/Regulatory Strategies
  • COMBINED PULL AND PUSH INCENTIVES
  • ORPHAN DRUG STATUS
    • TABLE 19: COMPARISON OF U.S. AND EU ORPHAN DRUG LEGISLATION AND PROCESS
    • Delinkage of Antibiotics
      • TABLE 20: LIST OF DELINKAGE MODELS
      • TABLE 21: LIST OF HYBRID MODELS

CHAPTER 5 - ANTIBIOTICS MARKET BY TYPE

  • MARKET SIZE ESTIMATION
  • MARKET SHARE ESTIMATION
  • GLOBAL ANTIBIOTICS MARKET BY CLASS
    • TABLE 22: GLOBAL ANTIBIOTICS MARKET BY CLASS, THROUGH 2020 ($ MILLIONS)
    • TABLE 23: GLOBAL ANTIBIOTICS MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
    • FIGURE 7: ANTIBIOTICS BY CLASS
  • BETA-LACTAM ANTIBIOTICS
    • TABLE 24: GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 25: GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS BY REGION, THROUGH 2020 ($ MILLIONS)
    • Extended Spectrum Beta-Lactamase
    • Metallo-Beta-Lactamases
      • FIGURE 8: TYPES OF BETA-LACTAM ANTIBIOTICS
    • Penicillins
      • TABLE 26: GLOBAL MARKET FOR PENICILLIN BY REGION, THROUGH 2020 ($ MILLIONS)
    • Types of Penicillin
      • TABLE 27: TYPES OF PENICILLIN BY BRAND NAME AND APPROVAL DATE
    • Cephalosporins
    • Side Effects
      • TABLE 28: GLOBAL MARKET FOR CEPHALOSPORIN BY REGION, THROUGH 2020 ($ MILLIONS)
    • Teflaro Driving the Cephalosporin Market
    • Generations of Cephalosporins
      • TABLE 29: GENERATIONS OF CEPHALOSPORIN
    • First-Generation Cephalosporins
      • TABLE 30: LIST OF FIRST-GENERATION CEPHALOSPORINS
    • Second-Generation Cephalosporins
      • TABLE 31: LIST OF SECOND-GENERATION CEPHALOSPORINS
    • Third-Generation Cephalosporins
    • Antipseudomonal Cephalosporins
      • TABLE 32: LIST OF THIRD-GENERATION CEPHALOSPORINS
    • Fourth-Generation Cephalosporins
      • TABLE 33: LIST OF FOURTH-GENERATION CEPHALOSPORINS
    • Fifth-Generation Cephalosporins
      • TABLE 34: LIST OF FIFTH-GENERATION CEPHALOSPORINS
    • Carbapenems
      • TABLE 35: GLOBAL MARKET FOR CARBAPENEM BY REGION, THROUGH 2020 ($ MILLIONS)
      • TABLE 36: TYPES OF CARBAPENEMS
  • QUINOLONES AND FLUOROQUINOLONES
    • TABLE 37: DEVELOPMENT HISTORY OF FLUOROQUINOLONES
    • TABLE 38: GLOBAL MARKET FOR FLUOROQUINOLONES BY GENERATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 39: GLOBAL MARKET FOR FLUOROQUINOLONES BY REGION, THROUGH 2020 ($ MILLIONS)
    • Generations of Quinolones
      • First-Generation Quinolones
      • Second-Generation Fluoroquinolones
        • TABLE 40: GLOBAL MARKET FOR SECOND-GENERATION FLUOROQUINOLONES BY REGION, THROUGH 2020 ($ MILLIONS)
      • Third-Generation Fluoroquinolones
        • TABLE 41: GLOBAL MARKET FOR THIRD-GENERATION FLUOROQUINOLONES BY REGION, THROUGH 2020 ($ MILLIONS)
        • Levofloxacin: A Major Driver of the Market for Third-Generation Fluoroquinolones
        • Fourth-Generation Fluoroquinolones
          • TABLE 42: GLOBAL MARKET FOR OTHER QUINOLONES BY REGION, THROUGH 2020 ($ MILLIONS)
          • TABLE 43: TYPES OF QUINOLONES
  • TETRACYCLINE
    • TABLE 44: GLOBAL MARKET FOR TETRACYCLINE BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 45: TYPES OF TETRACYCLINE
  • MACROLIDES
    • TABLE 46: GLOBAL MARKET FOR MACROLIDE BY REGION, THROUGH 2020 ($ MILLIONS)
    • Ketolides
      • Ketek
        • TABLE 47: TYPES OF MACROLIDES/KETOLIDES
  • OTHER ANTIBIOTICS
    • Pseudomonas Aeruginosa
      • TABLE 48: GLOBAL MARKET FOR OTHER ANTIBIOTICS BY REGION, THROUGH 2020 ($ MILLIONS)

CHAPTER 6 - VETERINARY ANTIBIOTICS MARKET

  • INTRODUCTION
    • TABLE 49: DIFFERENCES BETWEEN ANTIBIOTIC USAGE IN ANIMALS AND HUMANS
    • TABLE 50: GLOBAL MARKET FOR VETERINARY ANTIBIOTICS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • VETERINARY APPLICATIONS
    • FEED APPLICATION
      • FDA to Phase out Antibiotics from Food Production
    • THERAPEUTIC APPLICATIONS
      • TABLE 51: GLOBAL MARKET FOR VETERINARY THERAPEUTIC ANTIBIOTICS BY TYPE, THROUGH 2020 ($ MILLIONS)
      • TABLE 52: GLOBAL MARKET FOR VETERINARY THERAPEUTIC ANTIBIOTICS BY ANIMAL TYPE, THROUGH 2020 ($ MILLIONS)
  • OTHER APPLICATIONS

CHAPTER 7 - COMPANY PROFILES

  • ASTRAZENECA
    • FINANCIALS
      • TABLE 53: ASTRAZENECA REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
    • DEVELOPMENTS
      • TABLE 54: ASTRAZENECA DEVELOPMENTS
  • BAYER HEALTHCARE AG
    • FINANCIALS
      • TABLE 55: BAYER REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
    • DEVELOPMENTS
  • CUBIST PHARMACEUTICALS
    • DEVELOPMENTS
      • TABLE 56: CUBIST PHARMACEUTICAL DEVELOPMENTS
  • GLAXOSMITHKLINE
    • FINANCIALS
      • TABLE 57: GSK REVENUES AND R & D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
    • DEVELOPMENTS
      • TABLE 58 GSK DEVELOPMENTS
  • JOHNSON & JOHNSON
    • FINANCIALS
      • TABLE 59: JOHNSON & JOHNSON REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
    • DEVELOPMENTS
      • TABLE 60: JOHNSON & JOHNSON DEVELOPMENTS
  • MERCK & CO.
    • FINANCIALS
      • TABLE 61: MERCK & CO. REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
    • DEVELOPMENTS
      • TABLE 62: MERCK & CO.DEVELOPMENTS
  • PFIZER
    • FINANCIALS
      • TABLE 63: PFIZER REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
    • DEVELOPMENTS
      • TABLE 64: PFIZER DEVELOPMENTS
    • RECENT MERGERS AND ACQUISITIONS
      • TABLE 65: LIST OF OTHER COMPANIES IN THE ANTIBIOTICS MARKET

CHAPTER 8 - CLINICAL TRIALS ON ANTIBIOTICS

  • FIGURE 9: ANTIBIOTICS IN PHASES I-III CLINICAL TRIALS, 2015 (%)
  • TABLE 66: ANTIBIOTIC COMPOUNDS IN PHASE III CLINICAL TRIALS, 2015
  • ANTIBIOTICS IN PHASE II CLINICAL TRIALS
    • TABLE 67: ANTIBIOTIC COMPOUNDS IN PHASE II CLINICAL TRIALS, 2015
  • ANTIBIOTICS IN PHASE I CLINICAL TRIALS
    • TABLE 68: ANTIBIOTIC COMPOUNDS IN PHASE I CLINICAL TRIALS, 2015
    • TABLE 69: NATURAL PRODUCTS IN CLINICAL TRIALS FOR ANTIBIOTIC ACTIVITY THAT REPRESENT NEW CHEMICAL CLASSES, 2015

CHAPTER 9 - OVERVIEW OF BACTERIA TYPES

  • DISEASE ORGANISMS, DIAGNOSTICS, CLINICAL MANIFESTATIONS AND TREATMENTS
    • TABLE 70: LIST OF GRAM-POSITIVE BACTERIA
    • TABLE 71: LIST OF GRAM-NEGATIVE BACTERIA
    • TABLE 72: LIST OF GRAM-NEGATIVE COCCI
    • TABLE 73: LIST OF GRAM-NEGATIVE RODS RELATED TO RESPIRATORY TRACT INFECTIONS
    • TABLE 74: LIST OF GRAM-NEGATIVE RODS RELATED TO THE ENTERIC TRACT
    • TABLE 75: LIST OF GRAM-NEGATIVE SPIROCHETES
    • TABLE 76: LIST OF GRAM-NEGATIVE OBLIGATE INTRACELLULAR PARASITES
    • TABLE 77: LIST OF MISCELLANEOUS BACTERIA

CHAPTER 10 - LIST OF ACRONYMS

  • LIST OF ACRONYMS

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL ANTIBIOTICS MARKET BY CLASS, THROUGH 2020 ($ MILLIONS)
    • TABLE 1: DIFFERENCES BETWEEN GRAM-NEGATIVE AND GRAM-POSITIVE BACTERIA
    • TABLE 2: CLASSIFICATION OF BACTERIA BY SHAPE
    • TABLE 3: PRINCIPLES FOR JUDICIAL USE OF ANTIBIOTICS
    • TABLE 4: INCIDENCE OF UPPER RESPIRATORY TRACT INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)
    • TABLE 5: COMMON CAUSATIVE MICROBES OF COMMUNITY AND HOSPITAL-ACQUIRED PNEUMONIA
    • TABLE 6: PREFERRED PHARMACOTHERAPY FOR MICROORGANISMS CAUSING BACTERIAL PNEUMONIA
    • TABLE 7: INCIDENCE OF COMMUNITY-ACQUIRED PNEUMONIA BY COUNTRY, 2010 (NUMBER/%)
    • TABLE 8: INCIDENCE OF URINARY TRACT INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)
    • TABLE 9: INCIDENCE OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)
    • TABLE 10: INCIDENCE OF BACTERIAL VAGINOSIS INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)
    • TABLE 11: U.S. LIFE EXPECTANCY AT BIRTH, 1920-2013 (YEARS)
    • TABLE 12: ANTIBIOTICS: YEAR OF INTRODUCTION, MODE OF ACTION AND TARGET SPECIES
    • TABLE 13: ANTIBIOTICS: MODE OF ACTION
    • TABLE 14: ESTIMATED DEATHS PER YEAR CAUSED BY AMR BY REGION, 2050 (NUMBER)
    • TABLE 15: TYPES OF ANTIBIOTICS AND METHODS OF RESISTANCE
    • TABLE 16: CURRENT AND EMERGING ANTIBIOTIC-RESISTANT BACTERIA
    • TABLE 17: BIOCHEMICAL MECHANISM OF ANTIBIOTIC RESISTANCE
    • TABLE 18: ADDITIONAL COST AND LENGTH OF STAY DUE TO ANTIBIOTIC-RESISTANT BACTERIA BY REGION
    • TABLE 19: COMPARISON OF U.S. AND EU ORPHAN DRUG LEGISLATION AND PROCESS
    • TABLE 20: LIST OF DELINKAGE MODELS
    • TABLE 21: LIST OF HYBRID MODELS
    • TABLE 22: GLOBAL ANTIBIOTICS MARKET BY CLASS, THROUGH 2020 ($ MILLIONS)
    • TABLE 23: GLOBAL ANTIBIOTICS MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 24: GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 25: GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 26: GLOBAL MARKET FOR PENICILLIN BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 27: TYPES OF PENICILLIN BY BRAND NAME AND APPROVAL DATE
    • TABLE 28: GLOBAL MARKET FOR CEPHALOSPORIN BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 29: GENERATIONS OF CEPHALOSPORIN
    • TABLE 30: LIST OF FIRST-GENERATION CEPHALOSPORINS
    • TABLE 31: LIST OF SECOND-GENERATION CEPHALOSPORINS
    • TABLE 32: LIST OF THIRD-GENERATION CEPHALOSPORINS
    • TABLE 33: LIST OF FOURTH-GENERATION CEPHALOSPORINS
    • TABLE 34: LIST OF FIFTH-GENERATION CEPHALOSPORINS
    • TABLE 35: GLOBAL MARKET FOR CARBAPENEM BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 36: TYPES OF CARBAPENEMS
    • TABLE 37: DEVELOPMENT HISTORY OF FLUOROQUINOLONES
    • TABLE 38: GLOBAL MARKET FOR FLUOROQUINOLONES BY GENERATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 39: GLOBAL MARKET FOR FLUOROQUINOLONES BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 40: GLOBAL MARKET FOR SECOND-GENERATION FLUOROQUINOLONES BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 41: GLOBAL MARKET FOR THIRD-GENERATION FLUOROQUINOLONES BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 42: GLOBAL MARKET FOR OTHER QUINOLONES BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 43: TYPES OF QUINOLONES
    • TABLE 44: GLOBAL MARKET FOR TETRACYCLINE BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 45: TYPES OF TETRACYCLINE
    • TABLE 46: GLOBAL MARKET FOR MACROLIDE BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 47: TYPES OF MACROLIDES/KETOLIDES
    • TABLE 48: GLOBAL MARKET FOR OTHER ANTIBIOTICS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 49: DIFFERENCES BETWEEN ANTIBIOTIC USAGE IN ANIMALS AND HUMANS
    • TABLE 50: GLOBAL MARKET FOR VETERINARY ANTIBIOTICS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 51: GLOBAL MARKET FOR VETERINARY THERAPEUTIC ANTIBIOTICS BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 52: GLOBAL MARKET FOR VETERINARY THERAPEUTIC ANTIBIOTICS BY ANIMAL TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 53: ASTRAZENECA REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
    • TABLE 54: ASTRAZENECA DEVELOPMENTS
    • TABLE 55: BAYER REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
    • TABLE 56: CUBIST PHARMACEUTICAL DEVELOPMENTS
    • TABLE 57: GSK REVENUES AND R & D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
    • TABLE 58: GSK DEVELOPMENTS
    • TABLE 59: JOHNSON & JOHNSON REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
    • TABLE 60: JOHNSON & JOHNSON DEVELOPMENTS
    • TABLE 61: MERCK & CO. REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
    • TABLE 62: MERCK & CO.DEVELOPMENTS
    • TABLE 63: PFIZER REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
    • TABLE 64: PFIZER DEVELOPMENTS
    • TABLE 65: LIST OF OTHER COMPANIES IN THE ANTIBIOTICS MARKET
    • TABLE 66: ANTIBIOTIC COMPOUNDS IN PHASE III CLINICAL TRIALS, 2015
    • TABLE 67: ANTIBIOTIC COMPOUNDS IN PHASE II CLINICAL TRIALS, 2015
    • TABLE 68: ANTIBIOTIC COMPOUNDS IN PHASE I CLINICAL TRIALS, 2015
    • TABLE 69: NATURAL PRODUCTS IN CLINICAL TRIALS FOR ANTIBIOTIC ACTIVITY THAT REPRESENT NEW CHEMICAL CLASSES, 2015
    • TABLE 70: LIST OF GRAM-POSITIVE BACTERIA
    • TABLE 71: LIST OF GRAM-NEGATIVE BACTERIA
    • TABLE 72: LIST OF GRAM-NEGATIVE COCCI
    • TABLE 73: LIST OF GRAM-NEGATIVE RODS RELATED TO RESPIRATORY TRACT INFECTIONS
    • TABLE 74: LIST OF GRAM-NEGATIVE RODS RELATED TO THE ENTERIC TRACT
    • TABLE 75: LIST OF GRAM-NEGATIVE SPIROCHETES
    • TABLE 76: LIST OF GRAM-NEGATIVE OBLIGATE INTRACELLULAR PARASITES
    • TABLE 77: LIST OF MISCELLANEOUS BACTERIA

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL ANTIBIOTICS MARKET BY CLASS, 2015 AND 2020 ($ MILLIONS)
    • FIGURE 1: CLASSIFICATION OF ANTIBIOTICS
    • FIGURE 2: CDC LIST OF HIGHLY CONCERNING BACTERIA, ACCORDING TO THREAT LEVEL
    • FIGURE 3: INCREASE IN AGING POPULATION, 2011 AND 2050
    • FIGURE 4: GLOBAL MARKET SHARES FOR ANTIBIOTIC COMPANIES, 2014 (%)
    • FIGURE 5: REASONS FOR LACK OF INNOVATION IN ANTIBIOTIC RESEARCH
    • FIGURE 6: STRATEGIES TO PROMOTE ANTIBIOTIC RESEARCH
    • FIGURE 7: ANTIBIOTICS BY CLASS
    • FIGURE 8: TYPES OF BETA-LACTAM ANTIBIOTICS
    • FIGURE 9: ANTIBIOTICS IN PHASES I-III CLINICAL TRIALS, 2015 (%)
Back to Top